Hepatitis B vaccine: immune responses in haemodialysis patients.
Antibody to hepatitis B surface antigen (anti-HBs) developed within six months in 80% of haemodialysis patients given either two or three 40 micrograms doses of hepatitis B vaccine. A total of 89% had anti-HBs after a booster dose given six months later. Anti-HBs titres were higher in patients who received three initial doses than in those who received only two doses, but the proportion of anti-HBs-positive patients was the same in the two groups. Male patients became anti-HBs positive less often than females and their antibody titres were lower.
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis*; D000917:Antibody Formation; D002353:Carrier State / Q000517:prevention & control; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D012306:Risk; D012737:Sex Factors; D013997:Time Factors; D014765:Viral Vaccines / Q000494:pharmacology*
D000914:Antibodies, Viral; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D014765:Viral Vaccines